Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study

समान संसाधन

• Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
  द्वारा: Kato, Terufumi, और अन्य
  प्रकाशित: (2017)
• Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
  द्वारा: Ko, Ryo, और अन्य
  प्रकाशित: (2021)
• Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer
  द्वारा: KITAGAWA, CHIYOE, और अन्य
  प्रकाशित: (2019)
• Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
  द्वारा: Adderley, Helen, और अन्य
  प्रकाशित: (2019)
• Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
  द्वारा: Zhang, Shu, और अन्य
  प्रकाशित: (2016)